Torrent drops out of Sanofi EU generics auction over price: report by Eric Sagonowsky Thursday, April 5, 2018 Sanofi is out another potential buyer for its European generics business as India-based Torrent Pharma exited deal talks, according to a report.
After two high-profile M&A fails, how did Sanofi win Bioverativ? by Tracy Staton Friday, February 9, 2018 Sanofi didn't just woo Bioverativ execs. It made a play with investor Alex Denner. The result? $85M for CEO John Cox and a 2018 EPS boost for Sanofi.
J&J's blockbuster Zytiga faces 2018 generic threat by Eric Sagonowsky Thursday, January 18, 2018 Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Kite chief up for $600M-plus payday in Gilead buyout by Tracy Staton Thursday, August 31, 2017 Kite investors are set for big gains with Gilead Sciences’ $180-per-share buyout—and founder Arie Belldegrun will reap a $597 million of that payday.
Pfizer's Prevnar and Enbrel falter in Q2, raising doubts by Arlene Weintraub Tuesday, August 1, 2017 Pfizer announced mixed results in its second quarter, marked by a revenue shortfall on two aging blockbusters.
Pfizer and partner Astellas give up on Xtandi in breast cancer by Eric Palmer Friday, July 28, 2017 There is troubling news for Pfizer and cancer med Xtandi. Pfizer and partner Astellas have given up trials of Xtandi in breast cancer.
Pfizer faces near-term challenges, analysts say by Eric Sagonowsky Friday, July 21, 2017 In lowering their rating, analysts with Credit Suisse highlighted some concerns with Pfizer's business going forward.
Pfizer's $14B deal gets more flak after ASCO shortfall by Tracy Staton Monday, June 5, 2017 Last summer’s most ballyhooed M&A deal—Pfizer’s $14 billion buyout of Medivation—doesn’t look so impressive anymore, thanks to data rolled out at ASCO.
